GENB (Generate Biomedicines) Marketable Securities: $99.85 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GENB Generate Biomedicines Inc GENB
6 GF Score
Price $15.63
! 1 Warning Sign
View Full Analysis

What is Generate Biomedicines Marketable Securities?

Generate Biomedicines GENB +4.48% 6 Marketable Securities is $99.85 Mil as of Dec. 2025. GuruFocus rates GENB with a GF Score™ of 6/100. The stock has 1 warning sign investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Generate Biomedicines's Marketable Securities for the quarter that ended in Dec. 2025 was $99.85 Mil.

Generate Biomedicines's annual Marketable Securities increased from . 20 ($0.00 Mil) to Dec. 2024 ($217.36 Mil) but then declined from Dec. 2024 ($217.36 Mil) to Dec. 2025 ($99.85 Mil).

Generate Biomedicines  (NAS:GENB) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Generate Biomedicines Marketable Securities Related Terms

Generate Biomedicines Marketable Securities Historical Data

* Premium members only.

The historical data trend for Generate Biomedicines's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Generate Biomedicines Marketable Securities Chart

Generate Biomedicines Annual Data
Trend Dec24 Dec25
Marketable Securities
217.36 99.85

Generate Biomedicines Semi-Annual Data
Dec24 Dec25
Marketable Securities 217.36 99.85
GENB
6GF Score
Generate Biomedicines Inc GENB
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Generate Biomedicines Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $99.85 Mil mean?
Generate Biomedicines (GENB) has a Marketable Securities of $99.85 Mil as of Dec. 2025. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Generate Biomedicines and its competitors.
Is Generate Biomedicines' Marketable Securities too high?
Generate Biomedicines' current Marketable Securities is $99.85 Mil. Overall, Generate Biomedicines has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Generate Biomedicines' Marketable Securities compare to ZYME and DMRA?
Generate Biomedicines' Marketable Securities of $99.85 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Generate Biomedicines and its competitors. Generate Biomedicines's current Marketable Securities is $99.85 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Generate Biomedicines stock overvalued right now?
Generate Biomedicines (GENB) has a current Marketable Securities of $99.85 Mil. The current Marketable Securities is $99.85 Mil. Generate Biomedicines' overall GF Score™ is 6/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Generate Biomedicines (GENB), the current Marketable Securities is $99.85 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Generate Biomedicines Business Description

Address 101 South Street, Suite 900, Somerville, MA, USA, 02143
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
6GF Score

Get the complete analysis for GENB

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.63
Price